
Italy · Biotechnology
Developing analytical systems to characterize next-generation cancer immunotherapy
PrivateFor profit
Set against 208 Biotechnology companies in Italy. The ring marks the typical peer.
Across all 5.9M companies: larger than 33% of those with a size listed; older than 5% of those with a founding year; website ranked #7,309,119 in the world, about 821 visits a month. 31 people list it on LinkedIn, and 8,535 follow it.
Cellply is a life-science company focused on developing next-generation analytical tools enabling a deep characterization cancer immunotherapies, cell therapies and cell-based biotherapeutics. Our goal is to support the development of novel cancer immunotherapies by accelerating the R&D, advancing the quality control and monitoring the clinical response to these treatments. Through the use of proprietary microfluidic technologies, highly-automated analytical instruments and AI-powered image and data analytics,… Read all
Cellply is a life-science company focused on developing next-generation analytical tools enabling a deep characterization cancer immunotherapies, cell therapies and cell-based biotherapeutics. Our goal is to support the development of novel cancer immunotherapies by accelerating the R&D, advancing the quality control and monitoring the clinical response to these treatments. Through the use of proprietary microfluidic technologies, highly-automated analytical instruments and AI-powered image and data analytics, the Cellply platform defines the function of the immune system one cell at a time, combining functional data with other multiplex data and providing an unprecedented single-cell analytical solution.
BiotechnologyHealth CareMedicalmicrosystemscell analysisdrug testingcell therapyimmunotherapysingle-cellpotencycell function
What the source datasets report. We have not watched these rounds ourselves.
$12M
raised in total across 6 rounds
Last raised Sept 2023, 3 years ago
Who started it and how it trades.
Everything the source datasets list about CellPly, field by field. Contact details are held but never shown.
The company8 fields
Where4 fields
Size and reach5 fields
Funding, as listed8 fields
About this record2 fields
Growth, as the source summarises it
CellPly may be growing as it has recently secured €3.6 million in funding, which is a strong indicator of investor confidence and financial backing for expansion. This capital infusion is aimed at setting the stage for future growth, suggesting that the company is in a position to scale its operations or invest in further development. The fact that this funding event is highlighted suggests that CellPly is actively pursuing growth opportunities within the biotechnology and health care industries.
208 Biotechnology companies in Italy, filtered by size, age and reach, ready to export with emails on Pro.